Stock Traders Buy High Volume of ACADIA Pharmaceuticals Put Options (NASDAQ:ACAD)

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) was the target of some unusual options trading activity on Monday. Investors acquired 6,078 put options on the company. This is an increase of approximately 323% compared to the average daily volume of 1,436 put options.

Wall Street Analysts Forecast Growth

ACAD has been the subject of a number of analyst reports. Deutsche Bank Aktiengesellschaft reduced their price objective on ACADIA Pharmaceuticals from $38.00 to $31.00 and set a “buy” rating for the company in a research report on Friday. HC Wainwright dropped their target price on ACADIA Pharmaceuticals from $37.00 to $33.00 and set a “buy” rating on the stock in a research report on Friday, September 25th. Weiss Ratings upgraded ACADIA Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a research note on Wednesday, August 12th. BMO Capital Markets reduced their price target on shares of ACADIA Pharmaceuticals from $36.00 to $34.00 and set an “outperform” rating for the company in a report on Thursday, September 24th. Finally, Bank of America restated a “buy” rating and set a $14.50 price target on shares of ACADIA Pharmaceuticals in a research report on Wednesday, July 29th. Fourteen analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $32.76.

ACADIA Pharmaceuticals Price Performance

ACAD opened at $20.22 on Wednesday. ACADIA Pharmaceuticals has a 12 month low of $19.69 and a 12 month high of $30.96. The stock has a market cap of $3.48 billion, a P/E ratio of 9.11 and a beta of 0.86. The stock’s 50 day moving average price is $27.31 and its 200 day moving average price is $24.17.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.18 earnings per share for the quarter, beating the consensus estimate of $0.07 by $0.11. ACADIA Pharmaceuticals had a return on equity of 9.03% and a net margin of 33.42%.The firm had revenue of $308.00 million for the quarter, compared to the consensus estimate of $296.55 million. During the same quarter in the previous year, the business earned $0.16 EPS. The firm’s revenue for the quarter was up 16.4% on a year-over-year basis. Equities analysts anticipate that ACADIA Pharmaceuticals will post 0.64 EPS for the current year.

Insider Transactions at ACADIA Pharmaceuticals

In other ACADIA Pharmaceuticals news, EVP Mark C. Schneyer sold 14,292 shares of the firm’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $29.22, for a total value of $417,612.24. Following the transaction, the executive vice president owned 67,828 shares of the company’s stock, valued at $1,981,934.16. This trade represents a 17.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Elizabeth Thompson sold 16,558 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Thursday, July 30th. The shares were sold at an average price of $26.13, for a total value of $432,660.54. Following the completion of the transaction, the executive vice president owned 18,994 shares of the company’s stock, valued at approximately $496,313.22. The trade was a 46.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 36,699 shares of company stock valued at $1,019,894. Insiders own 26.20% of the company’s stock.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. Nykredit A S acquired a new position in ACADIA Pharmaceuticals during the 2nd quarter valued at about $38,000. Integrated Wealth Concepts LLC bought a new stake in shares of ACADIA Pharmaceuticals during the 2nd quarter worth about $50,000. Global Retirement Partners LLC acquired a new stake in shares of ACADIA Pharmaceuticals in the 2nd quarter worth approximately $64,000. GAMMA Investing LLC lifted its stake in shares of ACADIA Pharmaceuticals by 15.6% in the 2nd quarter. GAMMA Investing LLC now owns 2,985 shares of the biopharmaceutical company’s stock worth $76,000 after acquiring an additional 402 shares during the period. Finally, Transamerica Financial Advisors LLC bought a new position in shares of ACADIA Pharmaceuticals in the second quarter valued at approximately $104,000. Institutional investors and hedge funds own 96.71% of the company’s stock.

ACADIA Pharmaceuticals News Roundup

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: The U.S. Patent and Trademark Office issued a Notice of Allowance for a patent covering weight-banded dosing of trofinetide, the active ingredient in Daybue for Rett syndrome. The patent is expected to extend U.S. protection through March 2041, supporting a longer commercial runway and potentially limiting generic competition. Acadia Announces Trofinetide Patent Allowance
• Positive Sentiment: Analyst coverage continues to reflect confidence in Acadia’s longer-term growth: HC Wainwright maintained a Buy rating and a $33 price target, while projecting rising EPS from $1.87 in fiscal 2027 to $3.40 in fiscal 2030. HC Wainwright ACAD Earnings Estimate
• Neutral Sentiment: HC Wainwright made small downward revisions to its fiscal 2027–2030 EPS estimates, trimming forecasts by $0.02 per share in each year. The reductions are modest, but suggest slightly lower expectations for future profitability despite the continued Buy rating.
• Negative Sentiment: Pomerantz LLP announced an investigation into potential claims on behalf of ACADIA investors. The announcement does not establish wrongdoing, but shareholder investigations can add reputational and legal uncertainty and pressure sentiment. Pomerantz ACAD Investor Alert
• Negative Sentiment: Unusually heavy put-option activity indicated increased bearish positioning: traders purchased 6,078 puts, about 323% above average daily volume, with puts substantially outnumbering calls. ACAD Put Options Activity

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing medicines for neurological and psychiatric disorders. The company is headquartered in San Diego, California, and conducts research and commercial activities primarily in the United States.

ACADIA’s marketed products include NUPLAZID (pimavanserin), an atypical antipsychotic approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. The company also markets DAYBUE (trofinetide), a therapy for Rett syndrome, a rare neurodevelopmental disorder.

Founded in 1993, ACADIA continues to advance a pipeline of therapies for central nervous system conditions, including additional neurological and psychiatric disorders.